Patents by Inventor Mei XIA

Mei XIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF
    Publication number: 20260176239
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: October 9, 2025
    Publication date: June 25, 2026
    Inventors: Michael MUTZ, Fang WANG, Mei XIA
  • Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
    Patent number: 12459902
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides 5 methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: November 4, 2025
    Assignee: Bausch + Lomb Ireland Limited
    Inventors: Michael Mutz, Fang Wang, Mei Xia
  • NLRP3 inflammasome inhibitors
    Patent number: 12378222
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: October 16, 2024
    Date of Patent: August 5, 2025
    Assignee: Novartis AG
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20250034114
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: October 16, 2024
    Publication date: January 30, 2025
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20240067627
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 29, 2024
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye
  • CRYSTALLINE FORMS OF 4-(7-HYDROXY-2-ISOPROPYL-4-OXO-4H-QUINAZOLIN-3-YL)-BENZONITRILE AND FORMULATIONS THEREOF
    Publication number: 20230286924
    Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides 5 methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 14, 2023
    Inventors: Michael MUTZ, Fang WANG, Mei XIA